Delivery Order SPE2DB25D7067-SPE2DB25FSWCM
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Procainamide 1 gram/10 milliliter vials with a ceiling value of $1,704.20 and an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Procainamide is an...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Procainamide 1 gram/10 mL vials with a ceiling value of $10,566.94. This firm fixed-price delivery order, with an ultimate completion date of August 21, 2025, represents a continuation of AmerisourceBergen's extensive federal pharmaceutical supply relationship. The contract was competitively awarded with no set-aside designation, consistent with the...
- The Defense Logistics Agency awarded a delivery order valued at $3,508.11 to AmerisourceBergen Drug Corp for the supply of Procainamide 1 gram/10 milliliter vials on August 27, 2025. This firm fixed price delivery order, with an ultimate completion date of August 28, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.999 billion global pharmaceutical support vehicle running through December 2026. The...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Procainamide 1 gram/10 milliliter vials with a ceiling value of $2,137.63. This is a firm fixed-price delivery order with an ultimate completion date of August 18, 2025, and represents a non-competitive, non-set-aside award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Procainamide 1 gram/10 milliliter vials. This is a firm fixed-price delivery order with a ceiling value of $4,741.01 and an ultimate completion date of August 4, 2025. The contract carries no set-aside designation, indicating it was awarded through open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Procainamide 1 gram/10 milliliter vials with a ceiling value of $3,164.53. This firm fixed-price delivery order, which is not set-aside, is scheduled for completion by August 14, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a critical...
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Procainamide 1 gram/10 mL vials. This firm fixed-price delivery order, valued at $6,447.79, is scheduled for completion by August 4, 2025, and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's capability to...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Procainamide 1 gram/10 milliliter vials with a ceiling value of $2,505.03. This is a firm fixed price delivery order with an ultimate completion date of July 24, 2025, and represents a non-competitive set-aside contract. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains its...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for Procainamide 1 gram/10 mL vials totaling $1,539.32 on September 4, 2025, with completion due by September 5, 2025. This competitively awarded, firm fixed-price delivery order represents a single pharmaceutical procurement under a larger contract vehicle. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical...
- The U.S. Defense Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Procainamide 1 gram/10 mL vials totaling $1,484.44. This non-set-aside, firm fixed-price delivery order is scheduled for completion by August 20, 2025, with performance to take place at the vendor's Conshohocken, Pennsylvania facility. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, was selected through...
- SPE2DB25D7067Indefinite Delivery Contract
- SPE2DB25D7067-SPE2DB25FSWCMDelivery Order
The Defense Logistics Agency awarded a $13,436.04 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Procainamide 1 gram/2 mL vials on September 25, 2025, with completion scheduled for September 26, 2025. This non-competitive, non-set-aside award is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999.999 billion and extends through December 2026. Procainamide is a cardiac antiarrhythmic medication used in military medical supply chains to support healthcare operations for active duty personnel, veterans, and other beneficiaries within the Defense Health System. AmerisourceBergen, a major pharmaceutical distributor, maintains an extensive portfolio of federal contracts supplying brand-name and generic medications, vaccines, and medical devices across multiple therapeutic domains. The SPE2DX contract serves as a comprehensive global pharmaceutical support vehicle enabling the company to fulfill diverse medical procurement needs across the department of defense healthcare infrastructure. DLA Troop Support Medical is planning to transition pharmaceutical supply contracts to the next generation Pharmaceutical Prime Vendor Global Program Generation V, which will involve multiple awards to separate regional contractors, ensuring continued competitive sourcing for critical military medical supplies.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.4k | 9/25/25 |